ReP USP - Resultado da busca

Artigo de periodico
Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis (2024)
Chapleau, Marianne; Joie, Renaud La; Yong, Keir; Agosta, Federica; Allen, Isabel Elaine; Apostolova, Liana; Best, John; Boon, Baayla D. C; Crutch, Sebastian; Grinberg, Lea Tenenholz
Source: Lancet neurology. Unidade: FM
Subjects: DOENÇA DE ALZHEIMER, COMPROMETIMENTO COGNITIVO LEVE, DEMÊNCIA, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHAPLEAU, Marianne et al. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet neurology, v. 23, n. 2, p. 168-177, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/59027. Acesso em: 16 nov. 2024.
APA
Chapleau, M., Joie, R. L., Yong, K., Agosta, F., Allen, I. E., Apostolova, L., et al. (2024). Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. Lancet neurology, 23( 2), 168-177. doi:10.1016/S1474-4422(23)00414-3
NLM
Chapleau M, Joie RL, Yong K, Agosta F, Allen IE, Apostolova L, Best J, Boon BDC, Crutch S, Grinberg LT. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis [Internet]. Lancet neurology. 2024 ; 23( 2): 168-177.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/59027
Vancouver
Chapleau M, Joie RL, Yong K, Agosta F, Allen IE, Apostolova L, Best J, Boon BDC, Crutch S, Grinberg LT. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis [Internet]. Lancet neurology. 2024 ; 23( 2): 168-177.[citado 2024 nov. 16 ] Available from: https://observatorio.fm.usp.br/handle/OPI/59027
Artigo de periodico
Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
Docherty, Kieran F; Ogunniyi, Modele O; Anand, Inder S; Desai, Akshay S; Diez, Mirta; Howlett, Jonathan G; Nicolau, Jose Carlos ; O'meara, Eileen; Verma, Subodh; Inzucchi, Silvio E
Source: Jacc-heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 16 nov. 2024.
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Artigo de periodico
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis (2022)
Wollenberg, Andreas; Marcoux, Danielle; I, Jonathan Silverberg; Aoki, Valeria ; Baselga, Eulalia; Zhang, Haixin; Levit, Noah A.; Taieb, Alain; Rossi, Ana B.
Source: Acta dermato-venereologica. Unidade: FM
Subjects: DERMATITE, CRIANÇAS, SINAIS E SINTOMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WOLLENBERG, Andreas et al. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta dermato-venereologica, v. 102, 2022Tradução . . Disponível em: https://doi.org/10.2340/actadv.v102.854. Acesso em: 16 nov. 2024.
APA
Wollenberg, A., Marcoux, D., I, J. S., Aoki, V., Baselga, E., Zhang, H., et al. (2022). Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis. Acta dermato-venereologica, 102. doi:10.2340/actadv.v102.854
NLM
Wollenberg A, Marcoux D, I JS, Aoki V, Baselga E, Zhang H, Levit NA, Taieb A, Rossi AB. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis [Internet]. Acta dermato-venereologica. 2022 ; 102[citado 2024 nov. 16 ] Available from: https://doi.org/10.2340/actadv.v102.854
Vancouver
Wollenberg A, Marcoux D, I JS, Aoki V, Baselga E, Zhang H, Levit NA, Taieb A, Rossi AB. Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis [Internet]. Acta dermato-venereologica. 2022 ; 102[citado 2024 nov. 16 ] Available from: https://doi.org/10.2340/actadv.v102.854
Artigo de periodico
Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study (2021)
Arruda, Luisa Karla de Paula ; Yang, A. C.; Aoki, Valeria ; Criado, R. F. J.; Pires, M. C.; Lupi, O.; Fabricio, L. H. Z.; Richman, D.; Silvi, S.
Source: Journal of investigational allergology and clinical immunology. Unidades: FMRP, FM
Subjects: DERMATITE DE CONTATO, PREVALÊNCIA, QUALIDADE DE VIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARRUDA, Luisa Karla de Paula et al. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study. Journal of investigational allergology and clinical immunology, v. 31, n. 3, p. 236-245, 2021Tradução . . Disponível em: https://doi.org/10.18176/jiaci.0478. Acesso em: 16 nov. 2024.
APA
Arruda, L. K. de P., Yang, A. C., Aoki, V., Criado, R. F. J., Pires, M. C., Lupi, O., et al. (2021). Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study. Journal of investigational allergology and clinical immunology, 31( 3), 236-245. doi:10.18176/jiaci.0478
NLM
Arruda LK de P, Yang AC, Aoki V, Criado RFJ, Pires MC, Lupi O, Fabricio LHZ, Richman D, Silvi S. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study [Internet]. Journal of investigational allergology and clinical immunology. 2021 ; 31( 3): 236-245.[citado 2024 nov. 16 ] Available from: https://doi.org/10.18176/jiaci.0478
Vancouver
Arruda LK de P, Yang AC, Aoki V, Criado RFJ, Pires MC, Lupi O, Fabricio LHZ, Richman D, Silvi S. Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study [Internet]. Journal of investigational allergology and clinical immunology. 2021 ; 31( 3): 236-245.[citado 2024 nov. 16 ] Available from: https://doi.org/10.18176/jiaci.0478
Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 16 nov. 2024.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure (2019)
Ponikowski, Piotr; Kirwan, Bridget-Anne; Anker, Stefan D.; Dorobantu, Maria; Drozdz, Jaroslaw; Fabien, Vincent; Filippatos, Gerasimos; Haboubi, Teba; Keren, Andre; Nicolau, José Carlos
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, DOENÇAS NUTRICIONAIS E METABÓLICAS, FERRO, COMPOSTOS INORGÂNICOS, HOSPITALIZAÇÃO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PONIKOWSKI, Piotr et al. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, v. 21, n. 12, p. 1651-1658, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1710. Acesso em: 16 nov. 2024.
APA
Ponikowski, P., Kirwan, B. -A., Anker, S. D., Dorobantu, M., Drozdz, J., Fabien, V., et al. (2019). Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. European journal of heart failure, 21( 12), 1651-1658. doi:10.1002/ejhf.1710
NLM
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/ejhf.1710
Vancouver
Ponikowski P, Kirwan B-A, Anker SD, Dorobantu M, Drozdz J, Fabien V, Filippatos G, Haboubi T, Keren A, Nicolau JC. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure [Internet]. European journal of heart failure. 2019 ; 21( 12): 1651-1658.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1002/ejhf.1710
Artigo de periodico
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes (2019)
Roe, Matthew T; Li, Qian H; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Goodman, Shaun G; Harrington, Robert A; Jukema, J. Wouter; Lopez-jaramillo, Patricio; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: DIRETRIZES PARA A PRÁTICA CLÍNICA, ISQUEMIA MIOCÁRDICA, DISLIPIDEMIAS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROE, Matthew T et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, v. 140, n. 19, p. 1578-1589, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.042551. Acesso em: 16 nov. 2024.
APA
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., et al. (2019). Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 140( 19), 1578-1589. doi:10.1161/CIRCULATIONAHA.119.042551
NLM
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551
Vancouver
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551
Artigo de periodico
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (2019)
Ray, Kausik K; Colhoun, Helen M; Szarek, Michael; Baccara-dinet, Marie; Bhatt, Deepak L; Bittner, Vera A; Budaj, Andrzej J; Diaz, Rafael; Goodman, Shaun G; Nicolau, José Carlos
Source: Lancet diabetes & endocrinology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DIABETES MELLITUS, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAY, Kausik K et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, v. 7, n. 8, p. 618-628, 2019Tradução . . Disponível em: https://doi.org/10.1016/S2213-8587(19)30158-5. Acesso em: 16 nov. 2024.
APA
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-dinet, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, 7( 8), 618-628. doi:10.1016/S2213-8587(19)30158-5
NLM
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Vancouver
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Artigo de periodico
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019)
White, Harvey D; Steg, Ph. Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Erglis, Andrejs; Goodman, Shaun G.; Nicolau, José Carlos
Source: European heart journal. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, INSUFICIÊNCIA CARDÍACA, ENZIMAS PROTEOLÍTICAS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WHITE, Harvey D et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, v. 40, n. 33, p. 2801-2809, 2019Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz299. Acesso em: 16 nov. 2024.
APA
White, H. D., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., et al. (2019). Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European heart journal, 40( 33), 2801-2809. doi:10.1093/eurheartj/ehz299
NLM
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1093/eurheartj/ehz299
Vancouver
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Nicolau JC. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial [Internet]. European heart journal. 2019 ; 40( 33): 2801-2809.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1093/eurheartj/ehz299
Artigo de periodico
Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study (2019)
Farkouh, Michael E; Domanski, Michael; Dangas, George D; Godoy, Lucas C; Mack, Michael J; Siami, Flora S; Hamza, Taye H; Shah, Binita; Stefanini, Giulio G; Sidhu, Mandeep S; Hueb, Whady Armindo
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: REVASCULARIZAÇÃO MIOCÁRDICA, SOBREVIDA, DIABETES MELLITUS, CORONARIOPATIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FARKOUH, Michael E et al. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, v. 73, n. 6, p. 629-638, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.11.001. Acesso em: 16 nov. 2024.
APA
Farkouh, M. E., Domanski, M., Dangas, G. D., Godoy, L. C., Mack, M. J., Siami, F. S., et al. (2019). Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, 73( 6), 629-638. doi:10.1016/j.jacc.2018.11.001
NLM
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
Vancouver
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
Artigo de periodico
Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial (2019)
Steg, Philippe Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Bregeault, Marie-France; Dalby, Anthony J; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, v. 140, n. 2, p. 103-112, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038840. Acesso em: 16 nov. 2024.
APA
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Bregeault, M. -F., Dalby, A. J., et al. (2019). Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140( 2), 103-112. doi:10.1161/CIRCULATIONAHA.118.038840
NLM
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Vancouver
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Artigo de periodico
Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial (2019)
Szarek, Michael; White, Harvey D; Schwartz, Gregory G; Alings, Marco; Bhatt, Deepak L; Bittner, Vera A; Chiang, Chern-En; Diaz, Rafael; Edelberg, Jay M; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, SÍNDROME CORONARIANA AGUDA, ESTATINAS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SZAREK, Michael et al. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 73, n. 4, p. 387-396, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.10.039. Acesso em: 16 nov. 2024.
APA
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 73( 4), 387-396. doi:10.1016/j.jacc.2018.10.039
NLM
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Vancouver
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Artigo de periodico
Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia (2019)
Ginsberg, Henry N; Tuomilehto, Jaakko; Hovingh, G. Kees; Cariou, Bertrand; Santos Filho, Raul Dias dos; Brown, Alan S; Sanganalmath, Santosh K; Koren, Andrew; Thompson, Desmond; Raal, Frederick J
Source: Cardiovascular drugs and therapy. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ERROS INATOS DO METABOLISMO, ENZIMAS PROTEOLÍTICAS, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GINSBERG, Henry N et al. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, v. 33, n. 1, p. 69-76, 2019Tradução . . Disponível em: https://doi.org/10.1007/s10557-019-06852-6. Acesso em: 16 nov. 2024.
APA
Ginsberg, H. N., Tuomilehto, J., Hovingh, G. K., Cariou, B., Santos Filho, R. D. dos, Brown, A. S., et al. (2019). Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Cardiovascular drugs and therapy, 33( 1), 69-76. doi:10.1007/s10557-019-06852-6
NLM
Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s10557-019-06852-6
Vancouver
Ginsberg HN, Tuomilehto J, Hovingh GK, Cariou B, Santos Filho RD dos, Brown AS, Sanganalmath SK, Koren A, Thompson D, Raal FJ. Impact of age on the efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia [Internet]. Cardiovascular drugs and therapy. 2019 ; 33( 1): 69-76.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1007/s10557-019-06852-6
Artigo de periodico
Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial (2018)
Dillinger, Jean-Guillaume; Nicolau, Jose C.
Source: Circulation-cardiovascular interventions. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, ANGIOPLASTIA TRANSLUMINAL PERCUTÂNEA CORONÁRIA, TROMBOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DILLINGER, Jean-Guillaume e NICOLAU, Jose C. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, v. 11, n. 6, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084. Acesso em: 16 nov. 2024.
APA
Dillinger, J. -G., & Nicolau, J. C. (2018). Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circulation-cardiovascular interventions, 11( 6). doi:10.1161/CIRCINTERVENTIONS.118.006084
NLM
Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
Vancouver
Dillinger J-G, Nicolau JC. Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial [Internet]. Circulation-cardiovascular interventions. 2018 ; 11( 6):[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCINTERVENTIONS.118.006084
Artigo de periodico
Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system (2018)
Bahia, Luciana R.; Santos, Raul D.; Araujo, Denizar V.; Rosa, Roger S.; Bahia, Luciana R.
Source: Archives of endocrinology metabolism. Unidade: FM
Subjects: PACIENTES INTERNADOS, CUSTOS DOS CUIDADOS DE SAÚDE, DOENÇAS CARDIOVASCULARES, HIPERCOLESTEROLEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BAHIA, Luciana R. et al. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, v. 62, n. 3, p. 303-308, 2018Tradução . . Disponível em: https://doi.org/10.20945/2359-3997000000030. Acesso em: 16 nov. 2024.
APA
Bahia, L. R., Santos, R. D., Araujo, D. V., Rosa, R. S., & Bahia, L. R. (2018). Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Archives of endocrinology metabolism, 62( 3), 303-308. doi:10.20945/2359-3997000000030
NLM
Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 nov. 16 ] Available from: https://doi.org/10.20945/2359-3997000000030
Vancouver
Bahia LR, Santos RD, Araujo DV, Rosa RS, Bahia LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system [Internet]. Archives of endocrinology metabolism. 2018 ; 62( 3): 303-308.[citado 2024 nov. 16 ] Available from: https://doi.org/10.20945/2359-3997000000030
Artigo de periodico
Clinical Genetic Testing for Familial Hypercholesterolemia (2018)
Sturm, Amy C.; Santos, Raul D.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 16 nov. 2024.
APA
Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
NLM
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Vancouver
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 16 nov. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) (2018)
Danchin, Nicolas; Santos, Raul D.
Source: European journal of preventive cardiology. Unidade: FM
Subjects: ESTATINAS, DOENÇAS CARDIOVASCULARES, COLESTEROL, LIPOPROTEÍNAS LDL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DANCHIN, Nicolas e SANTOS, Raul D. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, v. 25, n. 10, p. 1087-1094, 2018Tradução . . Disponível em: https://doi.org/10.1177/2047487318777079. Acesso em: 16 nov. 2024.
APA
Danchin, N., & Santos, R. D. (2018). Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). European journal of preventive cardiology, 25( 10), 1087-1094. doi:10.1177/2047487318777079
NLM
Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/2047487318777079
Vancouver
Danchin N, Santos RD. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS) [Internet]. European journal of preventive cardiology. 2018 ; 25( 10): 1087-1094.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/2047487318777079
Artigo de periodico
Familial hypercholesterolaemia (2017)
Defesche, Joep C.; Gidding, Samuel S.; Harada-Shiba, Mariko; Santos Filho, Raul Dias dos; Wierzbicki, Anthony S.
Source: Nature reviews disease primers. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, COLESTEROL, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DEFESCHE, Joep C. et al. Familial hypercholesterolaemia. Nature reviews disease primers, v. 3, 2017Tradução . . Disponível em: https://doi.org/10.1038/nrdp.2017.93. Acesso em: 16 nov. 2024.
APA
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Santos Filho, R. D. dos, & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews disease primers, 3. doi:10.1038/nrdp.2017.93
NLM
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Vancouver
Defesche JC, Gidding SS, Harada-Shiba M, Santos Filho RD dos, Wierzbicki AS. Familial hypercholesterolaemia [Internet]. Nature reviews disease primers. 2017 ; 3[citado 2024 nov. 16 ] Available from: https://doi.org/10.1038/nrdp.2017.93
Artigo de periodico
Palliative care in interstitial lung disease: living well (2017)
Kreuter, Michael; Kairalla, Ronaldo Adib
Source: Lancet respiratory medicine. Unidade: FM
Subjects: QUALIDADE DE VIDA, CUIDADOS PALIATIVOS, DOENÇAS PULMONARES INTERSTICIAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KREUTER, Michael e KAIRALLA, Ronaldo Adib. Palliative care in interstitial lung disease: living well. Lancet respiratory medicine, v. 5, n. 12, p. 968-980, 2017Tradução . . Disponível em: https://doi.org/10.1016/S2213-2600(17)30383-1. Acesso em: 16 nov. 2024.
APA
Kreuter, M., & Kairalla, R. A. (2017). Palliative care in interstitial lung disease: living well. Lancet respiratory medicine, 5( 12), 968-980. doi:10.1016/S2213-2600(17)30383-1
NLM
Kreuter M, Kairalla RA. Palliative care in interstitial lung disease: living well [Internet]. Lancet respiratory medicine. 2017 ; 5( 12): 968-980.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-2600(17)30383-1
Vancouver
Kreuter M, Kairalla RA. Palliative care in interstitial lung disease: living well [Internet]. Lancet respiratory medicine. 2017 ; 5( 12): 968-980.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/S2213-2600(17)30383-1

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies